Mean arterial pressure (MAP), terlipressin, and hepatorenal syndrome-acute kidney injury (HRS-AKI) are closely interconnected in the treatment of this severe condition. HRS-AKI is a life-threatening complication of advanced liver disease, characterized by renal dysfunction due to reduced renal perfusion.
Mean arterial pressure (MAP), terlipressin, and hepatorenal syndrome-acute kidney injury (HRS-AKI) are closely interconnected in the treatment of this severe condition. HRS-AKI is a life-threatening complication of advanced liver disease, characterized by renal dysfunction due to reduced renal perfusion. Terlipressin, a vasopressin analog, is a key pharmacological agent used to reverse HRS-AKI by improving renal blood flow and function.
### Relationship Between MAP, Terlipressin, and HRS-AKI:
1. **Terlipressin and MAP**: Terlipressin works by causing vasoconstriction in the splanchnic (abdominal) circulation, which redistributes blood flow to vital organs, including the kidneys. This leads to an increase in MAP, a critical factor in improving kidney perfusion and function. In the phase 3 clinical trials (REVERSE and CONFIRM), terlipressin was shown to significantly increase MAP compared to placebo. For instance, on day 1 of treatment, the terlipressin group had a MAP of 85 mm Hg compared to 75 mm Hg in the placebo group, with sustained increases observed over time.
2. **MAP and HRS-AKI Reversal**: The post hoc analysis revealed that each 5 mm Hg increase in MAP was associated with a 17% higher likelihood of HRS-AKI reversal (hazard ratio: 1.17). This underscores the importance of MAP as a pharmacodynamic target in the treatment of HRS-AKI.
3. **Mediation Analysis**: The study found that MAP mediated the effect of terlipressin on HRS-AKI reversal, with an average of 33% of the treatment effect being mediated through MAP. This indicates that the increase in MAP is a key mechanism by which terlipressin achieves its therapeutic effect.
### Conclusion:
Terlipressin effectively increases MAP, which plays a crucial role in reversing HRS-AKI. The findings highlight the importance of monitoring and targeting MAP as part of the therapeutic strategy for managing HRS-AKI.
Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...
Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.